Molecular Docking of Seaweed-Derived Drug Fucoxanthin Against the Monkeypox Virus

Ramakrishnan Nikitha1, Klg Afeeza1, Vasugi Suresh2

  • 1Physiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, IND.

Cureus
|May 23, 2024
PubMed

Insights

Seaweed-derived fucoxanthin shows promise as an antiviral agent against the monkeypox virus (MPXV). In silico analysis revealed strong binding affinity between fucoxanthin and MPXV target proteins, indicating potential therapeutic applications.

Area of Science:

  • Computational Biology
  • Marine Biotechnology
  • Virology

Background:

  • Monkeypox virus (MPXV), a zoonotic virus from the Poxviridae family, poses a public health concern.
  • Marine macroalgae (seaweeds) are rich sources of bioactive compounds with demonstrated antiviral properties.
  • In silico analysis offers a computational approach to study biological systems and predict molecular interactions.

Purpose of the Study:

  • To investigate the potential of a seaweed-derived compound, fucoxanthin, as a therapeutic agent against MPXV.
  • To perform an in silico examination of the protein-ligand interaction between fucoxanthin and MPXV target proteins.

Main Methods:

  • Utilized molecular docking analysis to predict binding affinity and interactions.
  • Obtained MPXV methyltransferase and fucoxanthin structures from Protein Data Bank and PubChem.
  • Employed AutoDockTools and Autogrid for docking simulations, with PyMOL for visualization.

Main Results:

  • Fucoxanthin exhibited a strong binding energy of -5.46 kcal/mol with MPXV methyltransferase.
  • Identified specific hydrogen bonding interactions between fucoxanthin and key amino acid residues in the MPXV protein.
  • The negative docking score indicates a favorable and strong binding affinity, suggesting efficacy.

Conclusions:

  • Fucoxanthin, a compound derived from seaweed, demonstrates significant antiviral activity against the monkeypox virus.
  • The study supports fucoxanthin as a potential candidate for developing novel MPXV therapeutics based on its protein-ligand interactions.

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...